Skip to page content
Back to overview

Jun 13, 2024

Novel clinical biomarker for hepatic steatosis

Life Sciences, Diagnostics/Biomarker

  • Applicable for detecting or grading hepatic steatosis
  • Fast, simple and inexpensive
  • Minimal non-invasive

Your contact

Dr. M. Charlotte Hemmer

E-Mail:
chemmer@baypat.de
Phone:
+49 (0) 89 5480177 - 29
Reference Number:
B82088

Challenge

The worldwide rise of obesity and metabolic syndrome has ledto an increasing prevalence of nonalcoholic fatty liver disease. A subset of the one-quarter of affected patients globally have nonalcoholic steatohepatitis, which is an inflammatory disease that often advances to cirrhosis and end-stage liver failure. The enormous number of affected patients is accompanied with substantial morbidity, mortality and healthcare costs, presenting an emerging clinical challenge. The worldwide rise of obesity and metabolic syndrome has led to an increasing prevalence of nonalcoholic fatty liver disease. A subset of the one-quarter of affected patients globally have nonalcoholic steatohepatitis, which is an inflammatory disease that often advances to cirrhosis and end-stage liver failure. The enormous number of affected patients is accompanied with substantial morbidity, mortality and healthcare costs, presenting an emerging clinical challenge.

Innovation

Shedding of CD46 from hepatocytes into circulation reflects a stress response of hepatocytes to fat loading, which appears to be connected with activation of innate-like lymphocyte responses; therefore, soluble CD46 is unlike other established clinical liver markers by measuring a different type of hepatocyte property indicating cell injury, synthetic function, detoxifying activity, fibrosis or systemic inflammation. Soluble CD46 is a promising clinical marker of patients with steatosis at risk of developing early liver inflammation, a prevalent subset that could benefit from earlier clinical detection and intervention.

Commercial Opportunities

- Applicable as an alternative or complement for detecting or grading hepatic steatosis

- Fast, simple and inexpensive compared to resource-intensive imaging methods

- Minimal non-invasive diagnostic tool - no need for liver biopsy

- Validation via immuno-competition assay - other immunological assays possible, e.g. ELISA

Development Status

TRL Level 6: Technology demonstrated in relevant environment

References

  • https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00219-6/fulltext

    Publication

Interested? Get in touch!

Contact a specific team member via the Team section or simply use our contact form for your request.

Privacy settings

This website uses cookies. Cookies improve its usage and help make this website better.
Privacy policy